This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schloesser, R. L.
Right arrow Articles by Zielen, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schloesser, R. L.
Right arrow Articles by Zielen, S.
Related Collections
Right arrow Infectious Disease & Immunity
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

PEDIATRICS Vol. 103 No. 5 May 1999, p. e60

ELECTRONIC ARTICLE:
Safety and Immunogenicity of an Acellular Pertussis Vaccine in Premature Infants

Received Jul 8, 1998; accepted Dec 7, 1998.

Rolf L. Schloesser, Doris Fischer, Walter Otto, Werner Rettwitz-Volk, Peter Herden, and Stefan Zielen

From the Children's University Hospital, Frankfurt, Germany.

Objectives.  To evaluate the safety and immunogenicity of a two-component acellular pertussis vaccine in preterm infants.

Study Design.  Fifty preterm infants (25-35 weeks of gestation; mean, 30.8 weeks) and 50 term infants as a control group received a two-component acellular pertussis vaccine irrespective of their biological age and actual weight. Adverse reactions were registered by parents on a diary card and reviewed on each visit. Antibodies against pertussis toxoid (PT) and filamentous hemagglutinin (FHA) were determined with an enzyme-linked immunosorbent assay before the first and after the third vaccination.

Results.  The infants of both groups showed an increase in geometric mean titers (GMT) against PT and FHA after vaccination (3 doses). There was a significant difference of antibody concentration between the preterm and the control group. The GMT for PT antibody of the preterm infants was 64.16 U/L, and for the term infants it was 98.96 U/L. The GMT for FHA was 50.92 U/L in preterm versus 86.02 U/L in the control group. Efficacy of the immunization (more than a fourfold increase of antibody concentration in each infant) was 93.5% in the preterm group with respect to PT and 82.6% with respect to FHA. The incidence of adverse reactions was low and comparable in both study groups.

Conclusion.  Immunization with an acellular pertussis vaccine is safe for preterm infants. The immune response is significantly lower compared with a control group of term infants, but efficacy is high.  Key words:  immunization. pertussis vaccine, preterm infant, adverse effects, immunogenicity.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Ann. Thorac. Surg.Home page
B. McAlvin, M. L. Clabby, P. M. Kirshbom, K. R. Kanter, B. E. Kogon, and W. T. Mahle
Routine Immunizations and Adverse Events in Infants With Single-Ventricle Physiology
Ann. Thorac. Surg., October 1, 2007; 84(4): 1316 - 1319.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child.Home page
J Bonhoeffer, C-A Siegrist, and P T Heath
Immunisation of premature infants
Arch. Dis. Child., November 1, 2006; 91(11): 929 - 935.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child. Fetal Neonatal Ed.Home page
M H Slack, D Schapira, R J Thwaites, C Schapira, J Bamber, M Burrage, J Southern, N Andrews, and E Miller
Acellular pertussis vaccine given by accelerated schedule: response of preterm infants
Arch. Dis. Child. Fetal Neonatal Ed., January 1, 2004; 89(1): F57 - F60.
[Abstract] [Full Text] [PDF]